Articles
Latest Articles
Commentaries
Deals
Distillery
Emerging Companies
Finance
Politics, Policy & Law
Product Development
Regulation
Targets & Mechanisms
Tools & Techniques
Current Editions
Search Archives
BCIQ
Company Profiles
Target Profiles
Product Profiles
Conferences
China Healthcare Summit
Bio€quity Europe
White Papers
Free Trial
/
Subscribe
Sign In
more_vert
Biocentury
Company Profiles
Target Profiles
Product Profiles
Free Trial Information
Export Pdf
Product
Deals
Articles
BioCentury
|
Jul 25, 2019
Distillery Therapeutics
A tumor-targeted Bavencio conjugate with enhanced antitumor efficacy
...to treat first-line renal cell carcinoma, Merkel cell carcinoma and urothelial cancer. SolaranRx Inc. has
SRX-1177
...
Read More
BioCentury
|
May 18, 2015
Clinical News
SRX-1177 regulatory update
...FDA granted Orphan Drug designation to
SRX-1177
to treat stage IIB-IV malignant melanoma.
SRX-1177
is in...
...to identify and deliver targeted radiation to receptor-expressing tumors. SolaranRx Inc. , Albuquerque, N.M. Product:
SRX-1177
...
Read More
Items per page:
10
1 - 2 of 2
Previous page
Next page